SGLT2抑制剂在CKD中:对所有患者都真的有效吗?
该文探讨SGLT2抑制剂在不同CKD亚组中的疗效差异。主要试验多纳入超重或肥胖的晚期CKD患者,而Alport综合征或多数免疫介导肾小球病等瘦型患者可能获益有限。新证据提示肾脏获益可能依赖BMI,BMI<25者获益甚微,亟需专门试验验证。
要点
- SGLT2抑制剂肾脏获益可能依赖BMI,高BMI者获益更大,BMI<25者获益甚微。
- 瘦型非糖尿病CKD进展机制涉及炎症、自身免疫或遗传异常,SGLT2抑制剂作用有限。
- 需专门临床试验评估被低估CKD亚组(含儿童)的疗效。
核心结论
- SGLT2抑制剂在糖尿病、肥胖和心衰相关CKD中疗效明确,但在瘦型非糖尿病CKD患者中的作用尚不明确。
研究设计与样本
- 本文为综述性文章,汇总主要临床试验、新出现证据、动物研究和分子数据。
主要发现
- 主要临床试验多纳入超重或肥胖的晚期CKD患者,其钠潴留、容量扩张和肾小球高滤过是疾病驱动因素。
- 新证据提示SGLT2抑制剂肾脏获益可能依赖BMI,高BMI者获益更大,BMI<25者可能获益甚微。
- 动物研究提示SGLT2抑制剂在某些遗传性和免疫介导肾病中肾脏保护作用有限。
- 分子数据显示SGLT2表达主要局限于近端小管,提示其在非高滤过机制驱动的CKD中作用有限。
临床怎么用
- 对瘦型非糖尿病CKD患者使用SGLT2抑制剂需谨慎评估,考虑个体化治疗策略。
局限性
- 被低估的CKD亚组(如Alport综合征、免疫介导肾小球病、儿童患者)缺乏专门临床试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively slow chronic kidney disease (CKD) progression and reduce cardiovascular events. However, their efficacy across all CKD subgroups remains uncertain. Major clinical trials primarily included overweight or obese patients with advanced CKD, where sodium retention, volume expansion and glomerular hyperfiltration are key disease drivers. In contrast, many underrepresented CKD subgroups, such as Alport syndrome or most immune-mediated glomerular disorders, often affect lean individuals whose CKD progression is not linked to these mechanisms. Emerging evidence suggests that the renal benefits of SGLT2 inhibitors may depend on body mass index (BMI), with greater effects observed in patients with higher BMI, while those with BMI <25 may show minimal/no benefit. This raises concerns about their applicability in lean, non-diabetic CKD patients, whose disease progression may involve alternative pathways, such as inflammation, autoimmunity or genetic abnormalities. Animal studies further suggest that SGLT2 inhibitors provide limited renal protection in certain genetic and immune-mediated kidney diseases. Additionally, molecular data indicate that SGLT2 expression is predominantly restricted to the proximal tubule, implying a limited role in CKD driven by non-hyperfiltration mechanisms. While SGLT2 inhibitors have revolutionized CKD treatment in diabetes, obesity and heart failure, their role in lean, non-diabetic patients remains unclear. Dedicated clinical trials are needed to assess their efficacy in underrepresented CKD subgroups, including pediatric patients, and ensure evidence-based, personalized treatment strategies.
引用
- Romagnani P. SGLT2 inhibitors in CKD: are they really effective in all patients? Nephrol Dial Transplant. 2025. PMID: 40053507. doi:10.1093/ndt/gfaf051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。